http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Fangqiu Zhang ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Joint Estimation of TOA and DOA in IR-UWB System Using Sparse Representation Framework
Fangqiu Wang,Xiaofei Zhang 한국전자통신연구원 2014 ETRI Journal Vol.36 No.3
This paper addresses the problem of joint time of arrival(TOA) and direction of arrival (DOA) estimation inimpulse radio ultra-wideband systems with a two-antennareceiver and links the joint estimation of TOA and DOA tothe sparse representation framework. Exploiting this link,an orthogonal matching pursuit algorithm is used forTOA estimation in the two antennas, and then the DOAparameters are estimated via the difference in the TOAsbetween the two antennas. The proposed algorithm canwork well with a single measurement vector and can pairTOA and DOA parameters. Furthermore, it has betterparameter-estimation performance than traditionalpropagator methods, such as, estimation of signalparameters via rotational invariance techniquesalgorithms matrix pencil algorithms, and other new jointestimationschemes, with one single snapshot. Thesimulation results verify the usefulness of the proposedalgorithm.
-
( Lai Wei ),( Qing Xie ),( Jin Lin Hou ),( Hong Tang ),( Qin Ning ),( Jun Cheng ),( Yuemin Nan ),( Lunli Zhang ),( Jun Li ),( Jianning Jiang ),( Megan Kim ),( Brian Mcnabb ),( Fangqiu Zhang ),( Gregor 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Chronic hepatitis C virus (HCV) infection remains a major health threat in China, affecting at least 10 million people, with approximately 58% having genotype (GT) 1 infection. There is a critical need for simple, all oral, direct-acting antiviral regimens to treat GT1 HCV in this region. Treatment with ledipasvir (LDV)/sofosbuvir (SOF) results in high sustained virologic response rates 12 weeks after therapy (SVR12) in GT1 HCV infected patients in clinical trials and real-world settings. This study evaluated the efficacy and safety of LDV/SOF for 12 weeks in Chinese patients with chronic GT1 HCV infection. Methods: Treatment experienced and treatment naïve patients with chronic GT1 HCV infection with no cirrhosis or with compensated cirrhosis were eligible to enroll in a single-arm, openlabel trial to receive a fixed dosed combination of LDV/SOF 90/400 mg daily for 12 weeks. The primary efficacy endpoint was SVR12 using the CAP/CTM HCV 2.0 assay (LLOQ =15 IU/mL) and the primary safety endpoint was adverse events (AEs) leading to LDV/SOF discontinuation. Results: A total of 206 Chinese patients were enrolled and treated. Of these, 50% were male, 16% had compensated cirrhosis, 49% were treatment-experienced, 76% had IL28B CC genotype, and 100% had GT1b HCV infection. The mean (range) age and body mass index of enrolled subjects were 47 (21-72) years and 23 (14-34) kg/m2, respectively. The overall SVR12 rate is 100% (206/206). All 32 patients with cirrhosis (15 of whom were treatment-experienced), achieved SVR12. There were no discontinuations due to AEs. No serious or severe AEs were assessed by the investigator as related to study drug and there were no deaths. Conclusions: Treatment with the single tablet regimen of LDV/SOF for 12 weeks resulted in 100% SVR12 and was well tolerated in treatment experienced and treatment naïve GT1 HCVinfected Chinese patients with and without cirrhosis.
ScienceON
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
